In-vitro activity of fosfomycin against vancomycin-resistant enterococci

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 2, 1999, Pages 211-217

  Allerberger, Franz ^a   Klare, Ingo ^b  

^a Inst of Hygiene and Social Medicine   (Austria)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; FOSFOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DILUTION; ENTEROCOCCUS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS GALLINARUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; FOSFOMYCIN; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN RESISTANCE;

EID: 0033001670     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.2.211     Document Type: Article

References (18)

1. Fernandez Lastra, F. C., Marino, E. L., Dominguez-Gil, A., Tabernero, J. M., Gonzalez Lopez, A. & Yuste Chaves, M. (1983). The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid. European Journal of Clinical Pharmacology 25, 333-8.
2. Uttley, A. H. C., Collins, C. H., Naidoo, J. & George, R. C. (1988). Vancomycin-resistant enterococci. Lancet i, 57-8.
3. Deutsches Institut für Normung e.V. (1992). DIN 58940, Teil 6: Methoden der Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika -Bestimmung der minimalen Hemmkonzentration nach der Agar-Dilutionsmethode. In DIN-Taschenbuch Medizinische Mikrobiologie und Immunologie, Normen und weitere Unterlagen. 2. Aufl., pp. 376-80. Beuth-Verlag, Berlin and Cologne.
4. Deutsches Institut für Normung e.V. (1992). DIN 58940, Teil 8: Methoden der Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika -Mikrodilution. In DIN-Taschenbuch Medizinische Mikrobiologie und Immunologie, Normen und weitere Unterlagen. 2. Aufl., pp. 381-4. Beuth-Verlag, Berlin and Cologne.
5. Grimm, H. & Haag, R. (1982). Empfindlichkeitsprüfung mit Fosfomycin im Agardiffusionstest auf Mueller-Hinton-Agar. Immunität und Infektion 10, 159-63.
6. Andrews, J. M., Baquero, F., Beltran, J. M., Canton, E., Crokaert, F., Gobernado, M. et al. (1983). International collaborative study on standardization of bacterial sensitivity to fosfomycin. Journal of Antimicrobial Chemotherapy 12, 357-61.
7. National Committee for Clinical Laboratory Standards. (1997). Performance Standards for Antimicrobial Disc Susceptibility Tests - Sixth Edition: Approved Standard M2-A6. NCCLS, Villanova, PA.
8. Deutsches Institut für Normung e.V. (1992). DIN 58940, Teil 3: Methoden der Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika -Agar-Diffusionstest. In DIN-Taschenbuch Medizinische Mikrobiologie und Immunologie, Normen und weitere Unterlagen. 2. Aufl., pp.354-60. Beuth-Verlag, Berlin and Cologne.
9. Anonymous (1998). In Vidai Arzneimittelverzeichnis Österreich 1998, pp. 678-9. OVP-Vidal Verlag, Innsbruck.
10. Moellering, R. C. (1997). VRE: what therapeutic options do we have? In Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997, Abstract S-145, p. 399. American Society for Microbiology, Washington, DC.
11. Barry, A. L., Pfaller, M. A., Fuchs, P. C., Tenover, F. C., Reller, L. B., Allen, S. D. et al. (1993). Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine. European Journal of Clinical Microbiology and Infectious Diseases 12, 352-6.
12. Fuchs, P. C., Barry, A. L. & Brown, S. D. (1997). Susceptibility testing quality control studies with fosfomycin tromethamine. European Journal of Clinical Microbiology and Infectious Diseases 16, 538-40.
13. Hamilton-Miller, J. M. (1992). In vitro activity of fosfomycin against 'problem' Gram-positive cocci. Microbios 71, 95-103.
14. Kayser, H. (1987). Activity of fosfomycin against grampositive bacteria. In New Aspects for Treatment with Fosfomycin, (Guggenbichler, J. P., Ed.), pp. 9-18. Springer Verlag, Vienna and New York.
15. Caron, F., Pestel, M., Gutmann, L., Humbert, G. & Lemeland, J. F. (1995). Synergy between ceftriaxone plus fosfomycin in the treatment of an experimental endocarditis due to vancomycin-susceptible or vancomycin-resistant Enterococcus faecium. In Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995, Abstract B 47, p. 34. American Society for Microbiology, Washington, DC.
16. Landman, D. & Quale, J. M. (1997). Management of infections due to resistant enterococci: a review of therapeutic options. Journal of Antimicrobial Chemotherapy 40, 161-70.
17. Pestel, M., Martin, E., Aucouturier, C., Lemeland, J.-F. & Caron, F. (1995). In vitro interactions between different β-lactam antibiotics and fosfomycin against bloodstream isolates of enterococci. Antimicrobial Agents and Chemotherapy 39, 2341-4.
18. Rice, L. B., Eliopoulos, C. T., Yao, J. D., Eliopoulos, G. M., Moellering, R. C. (1992). In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagnostic Microbiology and Infectious Disease 15, 173-6.